Gilead Sciences (NASDAQ:GILD)‘s stock had its “neutral” rating reaffirmed by Zacks in a note issued to investors on Thursday. They currently have a $78.00 target price on the stock. Zacks‘s target price would suggest a potential upside of 5.55% from the stock’s previous close. Gilead Sciences, Inc. (NASDAQ:GILD) shares after opening at $74.85 moved to $76.80 on last trade day and at the end of the day closed at $74.08. Company price to sales ratio in past twelve months was calculated as 8.33 and price to cash ratio as 16.61. Gilead Sciences, Inc. (NASDAQ:GILD) showed a positive weekly performance of 3.46%.
Athersys, Inc. (NASDAQ: ATHX) announced interim results from the Phase 2 clinical study of the administration of Athersys’ MultiStem® cell therapy to treatment refractory ulcerative colitis (UC) patients being conducted by Pfizer, Inc. The study results demonstrate favorable safety and tolerability for MultiStem through 8 weeks following treatment. Athersys, Inc. (NASDAQ:ATHX) shares fell -51.28% in last trading session and ended the day on $1.33. ATHX return on equity ratio is recorded as -218.90% and its return on assets is -124.40%. Athersys, Inc. (NASDAQ:ATHX) yearly performance is -38.14%.
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, announced the Department of Defense (DoD) will provide funding towards a new clinical trial with NeuVax to prevent breast cancer recurrence in high-risk HER2 3+ patients. The grant, a Breast Cancer Research Program (BCRP) Breakthrough Award, was obtained by Elizabeth A. Mittendorf, M.D., Associate Professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center who will oversee the investigator-sponsored trial. Galena will support the trial with study drug and funding and will have access to the research to support ongoing registrational studies. Galena Biopharma Inc (NASDAQ:GALE) shares moved up 4.37% in last trading session and was closed at $2.39, while trading in range of $2.25-$2.65.Galena Biopharma Inc (NASDAQ:GALE) year to date performance is -51.81%.
The Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Apr. 2 announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Mr. Cole will be responsible for global business and corporate development, licensing and strategic planning. He will report to ARIAD’s chairman and chief executive officer, Harvey J. Berger, M.D. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) weekly performance is -5.28%. On last trading day company shares ended up $7.00. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) distance from 50-day simple moving average is -12.04%. Analysts mean target price for the company is $9.06.
Leave a Reply